# **Position Summary**The DIAN-TU launched the first anti-amyloid Alzheimer's prevention trials platform with two drugs and a third drug launching in 2017 with future drug arms planned. The DIAN-TU works with the National Institutes of Health, global academic centers of excellence, government regulatory agencies (FDA and EMA), pharma and philanthropic groups (e.g., Alzheimer's Association and GHR Foundation). The DIAN-TU's Clinical and Research Fellowship in clinical studies in autosomal dominant Alzheimer's disease at WashU Medicine is designed to develop competent physicians and independent investigators in clinical dementia research and trials. In addition to clinical and therapeutic studies to detect and understand treatment and prevention of autosomal dominant Alzheimer's disease, the DIAN-TU is involved in imaging, biomarker and genetic projects to better understand the causes, preclinical progression and pathology of Alzheimer's disease. We encourage i...